ADVI’s Vice President, Dr. Michael Kolodziej, talked to The American Journal of Managed Care about the side effects of first-gen BTK inhibitors
“The thinking is that the reduced cardiovascular side effects, the reduced bleeding, are going to allow a better persistence on the second-generation drugs”
[el-text]
Written by Maggie L. Shaw
***excerpt***
“The thinking is that the reduced cardiovascular side effects, the reduced bleeding, are going to allow a better persistence on the second-generation drugs”
***end excerpt***
[/el-text]
View full article here
Reach out
Own your edge
We don’t just guide the market. We shape it. Map your market access moves with #ADVIIntelligence. Proven advantage. Unmatched partnership.